Cook Islands vs Samoa: Statin use vs. average non-HDL cholesterol levels
Cook Islands
3.7
in 2018
Samoa
3.7
in 2018
Cook Islands rank
12th
Samoa rank
12th
Statin use vs. average non-HDL cholesterol levels over time
- Cook Islands
- Samoa
How they compare
Cook Islands currently reports 3.7 against 3.7 in Samoa, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Cook Islands ahead.
Cook Islands ranks 12th and Samoa ranks 12th of 191 countries.
Cook Islands has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Cook Islands | Samoa | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4 | 3.58 | 0.42 | Cook Islands |
| 1990s | 3.97 | 3.74 | 0.23 | Cook Islands |
| 2000s | 3.87 | 3.7 | 0.17 | Cook Islands |
| 2010s | 3.74 | 3.7 | 0.0444 | Cook Islands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Cook Islands or Samoa?
- Cook Islands, at 3.7 against 3.7 in Samoa as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Cook Islands and Samoa?
- 0, with Cook Islands ahead.
- How many years of comparable data are there for Cook Islands and Samoa?
- 39 years are reported by both, from 1980 to 2018.
- How do Cook Islands and Samoa rank globally for statin use vs. average non-hdl cholesterol levels?
- Cook Islands ranks 12th and Samoa ranks 12th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.